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She 2005 Annual Scientific Session of the American
ollege of Cardiology (ACC) was arguably the most suc-
essful annual meeting sponsored by the College. There
ere more high-visibility late-breaking clinical trials pre-
ented than ever before. Some of these studies are likely to
ave substantive impact on the practice of cardiology. In
his Supplement, the topic track chairs ably summarize the
ighlights in their respective fields. However, handicapping
he most important abstracts in real time is usually trumped
y the wisdom gained from hindsight. It may take five years
r longer to discern the truly important contributions, and it
s just as likely to be an overlooked single-center study as it
s a high-profile late-breaking clinical trial. With this
isclaimer in mind, we have chosen to provide a perspective
n several studies that we believe will become recognized as
mong the most important to emerge from the 2005 ACC
nnual Scientific Session.
The Cardiac Resynchronization-Heart Failure (CARE-
F) trial compared the time to death or hospitalization for
cardiovascular event in patients with New York Heart
ssociation (NYHA) functional class III or IV heart failure
ho were randomly assigned to either medical therapy or to
edical therapy plus a resynchronization pacemaker (1).
emarkably, there was an absolute 10% mortality benefit in
atients who received a resynchronization device. Similar to
ost previous trials, this study confirmed a device-related
enefit in quality of life, symptoms, NYHA functional class,
nd left ventricular (LV) function. However, this is the first
tudy to demonstrate a mortality benefit from a resynchro-
ization pacemaker. To what was this outcome attributable?
rimarily to a decrease in the incidence in death due to
rogressive heart failure and sudden cardiac death. Also
oteworthy, these benefits were seen in both patients with
schemic and nonischemic cardiomyopathy. Therefore, de-
reasing the degree of dyssynchrony and improving LV
erformance by resynchronization therapy translates directly
nto a significant mortality benefit. Extrapolating from the
omparison of Medical Therapy, Pacing, and Defibrillation
n Heart Failure (COMPANION) trial (2), it would be
easonable to surmise that an additional mortality benefit
ould be observed with a combined resynchronization-
efibrillator device because of further reduction in the
ncidence of sudden cardiac death.
An innovative remote method (implantable pressure-
ensing lead in the right ventricular outflow tract connectedi
From the Department of Medicine and Division of Cardiology, Cornell University
edical Center, New York, New York.o an implantable monitor the size of a pacemaker) to
ontinuously monitor intracardiac pressures and manage
atients with congestive heart failure was introduced in the
hronicle Offers Management to Patients with Advanced
igns and Symptoms of Heart Failure (COMPASS-HF)
rial (3). This single-blind study randomized patients to
eceive either therapy guided by device-based hemodynamic
onitoring or to receive therapy independent of the device
control group). Although an overall 22% reduction in heart
ailure-related events among the study group did not achieve
tatistical significance, a 41% reduction (p  0.03) in events
as observed in the pre-specified NYHA functional class III
ubgroup of patients, which comprised 85% of enrollment.
his study highlights the continuing trend toward device-
ased therapy in patients with congestive heart failure (resyn-
hronization pacemakers, defibrillators, ventricular assist
evices as destination therapy, and now continuous hemo-
ynamic monitoring). If the utility of the monitor can be
onfirmed and the technology further developed, it would
e an obvious and relatively small step to bundle this feature
ith the other heart failure devices presently available.
Several late-breaking clinical trials of pharmacologic ther-
pies warrant discussion based on their potential implica-
ions for future care and research. The Women’s Health
tudy examined the effect of low-dose every-other-day
spirin versus placebo on the primary prevention of first
ardiovascular event in nearly 40,000 healthy women (4). In
ontrast to the clear benefit of aspirin on reducing the risk
f myocardial infarction (MI) in men (4,5), aspirin use was
ot associated with a decreased risk of fatal or nonfatal MI
n the overall population of women (relative risk [RR] 1.02,
5% confidence interval [CI] 0.84 to 1.25, p  0.83) and
ith only a nonsignificant 9% decreased risk of major
ardiovascular events (95% CI 0.80 to 1.03, p  0.13).
However, although aspirin use has not been found to
ignificantly reduce the risk of stroke in men (1), low-dose
spirin use in women was associated with a significant 17%
eduction in the risk of stroke (95% CI 0.69 to 0.99, p 
.04), driven by a 24% reduction in the risk of the more
ommon ischemic stroke (95% CI 0.63 to 0.93, p  0.009)
nd a nonsignificant increased risk of the less common
emorrhagic stroke (RR 1.24, 95% CI 0.82 to 1.87, p 
.31). As would be expected, aspirin use was associated with
higher risk of major gastrointestinal bleeding requiring
ransfusion (RR 1.40, 95% CI 1.07 to 1.83, p  0.02).
ubgroup analysis in this study (4) was of particular signif-
cance for the finding that aspirin use was shown to decrease
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June 7, 2005:2B–3B ACC 2005 Annual Session Highlightshe risk of major cardiovascular events, MI, and ischemic
troke in women 65 years or older, a subgroup with the
ighest event rates (4). This study (4) highlights the
mportance of carefully examining biologic differences be-
ween men and women in the design and interpretation of
linical trials (6) and leaves decisions on the role of aspirin
or primary prevention of cardiovascular disease open to
iscussion between women and their physicians (4,6).
The Treating to New Targets (TNT) investigators (7)
resented evidence on the efficacy and safety of reducing
ow-density lipoprotein (LDL) cholesterol levels to 70
g/dl compared with the goal of 100 mg/dl based on
urrent guidelines (8), in patients with chronic coronary
eart disease. After a run-in phase of treatment with
torvastatin 10 mg daily, the 10,001 patients with LDL
holesterol levels 130 mg/dl were randomly assigned to
ouble-blind therapy with either 10 mg or 80 mg of
torvastatin per day. Compared with patients given 10 mg
f atorvastatin, the 80-mg therapy group had lower mean
DL levels during treatment (77 vs. 101 mg/dl) and
ignificant reductions in the risk of a major coronary event,
ny coronary event, cerebrovascular event, hospitalization
or heart failure, and any cardiovascular event. The decreases
n risk seen with higher-dose atorvastatin were associated
ith an increased incidence of persistent liver enzyme
levations (1.2% vs. 0.2%), but no significant increases
ccurred in creatine kinase levels, myalgias, or rhabdomy-
lysis. However, there was no significant reduction in
verall mortality, with the decrease in deaths from coronary
isease balanced by an increase in the number of deaths not
rom cardiovascular causes, although the study was not
owered to detect changes in the risk of death from any
ause (7,9). Although these findings suggest that further
owering of LDL cholesterol below currently recommended
evels may provide additional cardiovascular benefits (7),
hey also raise some concerns about the safety of an 80 mg
ose and whether other means of achieving an LDL
holesterol level of 70 mg/dl will be equally effective in
educing the risk of cardiovascular events (9).
A recent trend in treating hypertension, emphasized in
oint National Commission-VII (10), is the common
eed for combination treatment regimens. The Anglo-
candinavian Cardiac Outcomes Trial (ASCOT) inves-
igators (11) presented data comparing cardiovascular
utcomes between a traditional beta-blocker/diuretic
egimen (atenolol  bendroflumethiazide) and a more
ontemporary calcium channel blocker (CCB)/angiotensin-
onverting enzyme (ACE) inhibitor (amlodipine  perin-
opril) antihypertensive regimen in more than 19,000 pa-
ients. All assigned medications were taken by a large
ajority of subjects, making the ASCOT study a trial of
egimens rather than a comparison of individual classes of
ntihypertensives. The blood pressure lowering arm of theSCOT study was stopped by its Data Safety Monitoring
oard in October 2004 when fewer than 75% of the planned
rimary end points had occurred because of a significant
4% lower all-cause mortality in the CCB/ACE inhibitor
rm. The rates of other events were also significantly lower
n the newer treatment combination, including reductions
f about 15% in all coronary end points and cardiovascular
vents and procedures and of nearly 25% in stroke and
ardiovascular death. Less rapid blood pressure control and
ore deleterious metabolic changes—including almost 50%
ore new-onset diabetes, 4.5 mg/dl lower high-density
ipoprotein cholesterol, and 25 mg/dl higher triglycerides—
ith the beta-blocker/diuretic regimen than with CCB/
CE inhibitor treatment, may have contributed to the
orse clinical outcomes with traditional treatment.
Finally, the results of the ASCOT study suggest that the
rognosis of hypertension, the most common cardiovascular
ondition, can be improved by newer antihypertensive
reatment combinations that lower blood pressure faster and
void metabolic side effects.
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